Feasibility Assessment of Facilitated Subcutaneous Immunoglobulin 1.0 G/Kg with Abbreviated Dose Ramp-Up and without Ramp-Up: A Phase 1 Tolerability and Safety Study in Healthy Adults (P6-4.003)
Zhaoyang Li(Guiyang Medical University), Leman Yel(Children's Hospital of Philadelphia), Kimberly Duff(Takeda (United States)), Enrique Rivera García(Takeda (United States)), Juan Carlos Rondón(Clinical Pharmacology of Miami), Dirk Lindner(Takeda (United States)), András Nagy(University of Szeged), Hakan Ay(Takeda (United States)), Noor M. Khaskhely(Takeda (United States))
Cited by 0
Related Papers
A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms
|Cardiovascular Drugs and Therapy|2024|38
Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference
|Journal of Clinical Immunology|2021|28
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study
|Immunotherapy|2024|5
Vitamin D and breast cancer
|Orvosi Hetilap|2014|4